In this section, the Lyme Disease Association (LDA) brings to your attention news on Lyme and other tick-borne diseases’ science that is being published in peer-review, news from Lyme organizations on events they are providing, other Lyme-related sources, and news from government sources that might impact the general public or those whose lives have been affected by tick-borne diseases. The LDA attempts to bring you factual information from credible sources with its news items. If the item is an opinion piece, that is generally noted. See submenu of News to the right.
Valneva and Pfizer have announced that the two companies have entered into an Equity Subscription Agreement and have updated their Collaboration and License Agreement terms for the Lyme disease vaccine candidate, VLA15. As previously announced, Pfizer plans to begin Phase 3 studies of VLA15 in Q3 2022.